Grants and Contributions:
Title:
The development of digestive tract-circumscribed PDE4 inhibitor prodrugs for the treatment of ulcerative colitis.
Agreement Number:
976749
Agreement Value:
$345,000.00
Agreement Date:
Aug 2, 2021 - May 31, 2022
Description:
Giiant Pharma develops new therapeutic for the gastrointestinal tract. The project aims to finalize the preclinical development and the production process to position the product for clinical trials.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Montreal, Quebec, CA H3B 1S6
Reference Number:
172-2021-2022-Q2-976749
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
835958596
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by -65 days. The total amended value is -155,000 dollars.
Amendment Date
Aug 3, 2022
Recipient's Operating Name:
Giiant Pharmaceutique
Recipient's Legal Name:
Giiant Pharma Inc.
Federal Riding Name:
Ville-Marie--Le Sud-Ouest--Île-des-Soeurs
Federal Riding Number:
24077
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
3254
Amendments: